News & Updates

Show Multimedia Only
Working out in the COVID aftermath: How intense can one go?
Working out in the COVID aftermath: How intense can one go?
26 Jun 2024 byAudrey Abella

Outpatients with post-COVID condition (PCC) generally tolerated exercise without significant worsening of symptoms or decline in aerobic performance after 48 hours. However, they had lower muscle strength and aerobic capacity than controls, and even showed signs of POTS* and myopathy in a randomized crossover trial.

Working out in the COVID aftermath: How intense can one go?
26 Jun 2024
Diabetes ups mortality risk in TB patients
Diabetes ups mortality risk in TB patients
25 Jun 2024 byStephen Padilla

People diagnosed with tuberculosis (TB) face a worse prognosis if they also have untreated or complicated diabetes mellitus (DM), according to a study.

Diabetes ups mortality risk in TB patients
25 Jun 2024
Longest ever PFS in advanced NSCLC CROWNs lorlatinib’s 5-year data
Longest ever PFS in advanced NSCLC CROWNs lorlatinib’s 5-year data
25 Jun 2024 byNatalia Reoutova

After 5 years of follow-up, median progression-free survival (PFS) has still not been reached in patients with advanced non-small-cell lung cancer (NSCLC) treated with lorlatinib in the phase III CROWN study, corresponding to the longest PFS ever reported with any single-agent molecular targeted treatment in advanced NSCLC and across all metastatic solid tumours.

Longest ever PFS in advanced NSCLC CROWNs lorlatinib’s 5-year data
25 Jun 2024